X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Patent Protection Lift-off For COVID-19 Vaccines; Not a Bright Choice

Content Team by Content Team
2nd December 2020
in News
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

The world of Pharmaceuticals is caught in the web of who brings out the vaccine and when scenario. The darkest hours that the world has been a witness to are from the last 10 months. However, every day, there is a ray of hope which pushes us to believe that all this is soon going to end the way it should be. The much-awaited invention of a COVID-19 vaccine that gets us back on to our feet is hopefully around the corner.

As we pen this down, Pfizer and BioNtech, Moderna, AstraZeneca have all shown much promise in going the right way. The clinical trials efficacy of each of them is a testament to their success. Pharmaceutical companies have invested big time in research and development that will result in effective and to the point manufacturing during the course of this pandemic.

According to Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, “Patent protection shouldn’t be lifted when it comes to building a dose as complex as this. If at all that happens, the quality assurance may take a big hit due to the involvement of the lesser expert staff as well non-compliances of the benchmarking practices”. He further adds that there is a strong probability of almost 10 vaccines coming out by next summer, but all that has to happen with rigorous, transparent and scientific scrutiny of the processes undertaken.

It is well to be noted that at the WTO level, countries such as India, South Africa have already proposed a temporary waiver when it comes to compulsory licensing for patented products. However, there has been strong opposition by USA, EU & Switzerland in this regard.

Cueni says that “There is no doubt a lot of politics is involved in this gamut of Intellectual Property and it shows a sort of disrespect to the entire pharmaceutical system that has developed with time. A minimum number of 50 quality assurance staff are required in carrying out effective monitoring and there are around hundreds of checks during the entire production process. There has never been an instance of a compulsory license being granted for a vaccine during a pandemic or otherwise and every member of the pharmaceutical fraternity have committed to a not-for-profit and socially responsible pricing matrix for COVID-19”.

Previous Post

A Go-Ahead Given By European Commission To Moderna For Supplying The Budding COVID-19 Vaccine

Next Post

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In